Skip to main content
. 1999 Dec;10(12):4441–4450. doi: 10.1091/mbc.10.12.4441

Figure 3.

Figure 3

Tumor-specific CTLs are capable of tumor lysis in all phases of the cell cycle. CTLs recognizing gp100+/MART-1+ tumor lines in the context of HLA-A2 were plated with recognized (HLA-A2+) and mismatched (HLA-A2) tumor targets at different E:T ratios. Results are shown for CTL 1520 versus melanoma line 624 (A) and CTL 1235 versus melanoma line 526 (B) at an E:T ratio of 10:1. Similar results were obtained at all E:T ratios and were repeated at least twice.